NCT06908122Not yet recruiting
Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
Source: ClinicalTrials.gov · Last updated 3 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The validity of laboratory biomarkers in the diagnosis of NAFLD is still not established, and adherence to a healthy dietary lifestyle for those patients in our community is not well studied.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 11 Mar 2025
- Start date
- 1 Apr 2025
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Assiut University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06908122
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Apr 2025 to the primary completion date, 1 Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving treatment with drugs known to promote liver steatosis (for example, tamoxifen, amiodarone, estrogen, or corticosteroids).
Other illness
- Patients diagnosed with viral hepatitis to avoid other causes of liver fibrosis. .
- Patients with malignant tumors or other severe organ dysfunction diseases.
Age
- Patients younger than 18 years old.
Other
- Patients with alcoholic fatty liver (more than three standard drinks per day for men or more than two standard drinks per day for women).
Who the study is looking for
- All adult patients attending outpatient clinics characterized by an age over 18 years.
- Patients diagnosed as NAFLD.
Age in the registry: 19 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.